Relay Therapeutics (RLAY) Earnings Date & Reports

Key Takeaways

• Relay Therapeutics is expected to report Q2 2026 results on or around August 6–7, 2026, with consensus EPS estimates ranging from -$0.39 to -$0.41 and revenue expectations between approximately $465,000 and $960,000.
• The company remains a pre-revenue clinical-stage biotech, meaning quarterly financials matter less than clinical pipeline updates, cash burn trajectory, and regulatory milestones.
• Wall Street sentiment is overwhelmingly bullish, with 14 analysts maintaining a "Strong Buy" consensus and an average 12-month price target of approximately $26.08, representing roughly 40% upside from recent trading levels.
• Lead asset zovegalisib (RLY-2608) continues to draw significant attention following positive clinical signals in breast cancer and vascular anomalies, with JPMorgan projecting potential peak sales exceeding $8 billion across those indications.
• Cash runway remains a critical investor focus, with current reserves estimated to fund operations into mid-2027, raising questions about potential financing needs.
• The stock has surged more than 450% over the past 12 months, reflecting growing confidence in the company's precision oncology platform, but also raising the bar for positive catalysts.

Earnings Context and Why It Matters

Relay Therapeutics sits at a pivotal juncture in its corporate trajectory. The company's proprietary Dynamo platform, which leverages protein motion dynamics to design targeted small-molecule drugs, has attracted substantial analyst and institutional interest over the past year. With its lead candidate zovegalisib advancing through Phase 3 trials in HR+/HER2- advanced breast cancer and additional studies in vascular anomalies, this Q2 report serves as a progress checkpoint. For a pre-revenue biotech, quarterly earnings are less about top-line numbers and more about clinical execution, enrollment updates, and balance sheet strength. Investors will parse management commentary for any signals on data readout timelines, regulatory engagement, and partnership discussions that could extend the company's financial runway.

Earnings Expectations

Wall Street analysts expect Relay Therapeutics to report a net loss between $0.39 and $0.41 per share for the second quarter of 2026, roughly flat compared to the -$0.41 per share reported in the same period last year. Revenue consensus sits in a broad range from approximately $465,000 to $960,000, reflecting the unpredictable nature of collaboration and licensing income at this stage of the company's lifecycle. In the prior Q1 2026 report, Relay posted a loss of $0.41 per share (missing the consensus estimate of approximately $0.35–$0.38) alongside revenue of $3 million, which also fell short of the $5.58 million consensus. Despite the miss, shares rose roughly 5%, underscoring that the market prioritizes pipeline progress over near-term financial metrics. For Q2, investors will watch research and development (R&D) expense trends closely as a proxy for clinical trial activity, as well as any update to the company's cash position. Relay ended Q1 with a balance sheet described as well-capitalized, though estimates suggest the current runway extends into mid-2027 absent new financing or partnership inflows.

AI Screener

Staying ahead of earnings season requires efficient tools to filter the market for actionable opportunities. Tickeron's AI Screener is an AI-powered stock and ETF discovery platform designed to help traders and investors scan thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, and fundamental metrics. The screener leverages artificial intelligence to surface breakout candidates, trending stocks, and emerging trade ideas far more efficiently than manual screening methods. For investors tracking clinical-stage biotech names like Relay Therapeutics, the AI Screener can help identify peers, monitor sector-wide momentum shifts, and spot technical patterns ahead of major catalysts such as earnings releases or clinical data readouts. Explore the screener to bring data-driven efficiency to your market research workflow.

Market Reaction and Investor Sentiment

Investor sentiment heading into Relay's Q2 report leans decisively bullish but comes with elevated expectations. The stock has appreciated more than 450% over the trailing 12 months, pushing its market capitalization to approximately $4 billion. Analyst activity has been robust: JPMorgan initiated coverage with an Overweight rating and a $28 price target in early July, Canaccord Genuity launched coverage with a Buy rating and a $29 target, and Goldman Sachs raised its target to $31 from $22, maintaining a Buy rating. Fourteen analysts now cover the stock with a unanimous "Strong Buy" consensus. However, this bullish positioning raises the stakes—any negative clinical signal, enrollment delay, or faster-than-expected cash burn could trigger outsized downside. Short interest stood at roughly 42.6 million shares in mid-July, representing about 13 days to cover, indicating a significant bearish contingent that could amplify volatility around the print. The market's reaction will likely hinge less on the EPS figure itself and more on qualitative pipeline commentary.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 print, several catalysts and risk factors will shape Relay Therapeutics' trajectory over the next 12 to 18 months.

The most consequential near-term event is the continued advancement of zovegalisib (RLY-2608) across its three active clinical programs. The Phase 3 ReDiscover-2 trial, evaluating the drug in combination with fulvestrant in HR+/HER2- advanced breast cancer patients who have progressed on CDK4/6 inhibitors, represents the company's most advanced registrational effort. JPMorgan's initiation note highlighted durable antitumor activity in heavily pretreated populations and rapid pharmacodynamic effects as measured by circulating tumor DNA (ctDNA) clearance. Any updates on enrollment progress or anticipated data readout timelines during the earnings call will be closely scrutinized.

Beyond breast cancer, the ReInspire trial in PI3Kα-driven vascular anomalies opens a second major market opportunity. Analysts project that this indication alone could generate peak sales of approximately $4.3 billion, roughly matching the breast cancer opportunity. Progress here diversifies the investment thesis beyond oncology.

On the financial front, cash management remains a central concern. With operating expenses running above $300 million annually and limited collaboration revenue, the company's ability to fund operations into mid-2027 implies a potential capital raise or partnership transaction within the next 12 to 18 months. Investors should listen for management commentary on partnering discussions, non-dilutive funding opportunities, and spending discipline.

Finally, the broader biotech financing environment and Federal Reserve interest rate policy will influence Relay's access to capital. A favorable rate backdrop supports risk-on positioning in pre-revenue biotech names, while tightening conditions could pressure valuations across the sector regardless of individual pipeline progress.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations